



IPTA
International Patent
& Trademark Agency


Company

AASTROM BIOSCIENCES, INC.



IPTA
International Patent
& Trademark Agency

Image mark



Pub. No. **WO/2014/089397**
International Application No. **PCT/US2013/073496**
Publication Date **12.06.2014**
International Filing Date **06.12.2013**
IPC **C12N 5/0775 (2010.01), C12N 5/071 (2010.01), C12N 5/0789 (2010.01)**
Applicants **AASTROM BIOSCIENCES, INC. [US/US]; Domino's Farms, Lobby K24 Frank Lloyd Wright Drive Ann Arbor, MI 48105 (US)**
Inventors **BARTEL, Ronnda, L.; (US).BOOTH, Erin; (US).ZEIGLER, Frank; (US)**
Priority Data **61/734,262 06.12.2012 US**
Title **(EN) COMPOSITIONS AND METHODS OF TREATING AND PREVENTING PULMONARY FIBROSIS(FR) COMPOSITIONS ET MÉTHODES DE TRAITEMENT ET DE PRÉVENTION DE LA FIBROSE PULMONAIRE**

Abstract

(EN)The present invention provides methods of treating and preventing pulmonary fibrosis, including idiopathic pulmonary fibrosis (IPF). Methods of the invention include administering to a subject with or at risk for pulmonary fibrosis an isolated cell composition for tissue repair comprising a mixed population of cells of hematopoietic, mesenchymal and endothelial lineage, wherein the viability of said cells is at least 80% and the composition contains: a) about 5-75% viable CD90+ cells with the remaining cells in said composition being CD45+; b) less than 2 µg/ml of bovine serum albumin; c) less than 1 mg/ml of a enzymatically active harvest reagent; and d) substantially free of mycoplasma, endotoxin, and microbial contamination.(FR)La présente invention concerne des méthodes de traitement et de prévention de la fibrose pulmonaire, comprenant la fibrose pulmonaire idiopathique. Les méthodes de l'invention incluent l'administration, à un sujet atteint ou risquant d'être atteint d'une fibrose pulmonaire, d'une composition de cellules isolées pour réparation tissulaire, comprenant une population mélangée de cellules de lignées hématopoïétiques, mésenchymateuses et endothéliales. La viabilité desdites cellules est d'au moins 80 %, et la composition contient les éléments suivants : a) environ 5 à 75 % de cellules CD90+ viables, les cellules restantes dans la composition étant CD45+; b) moins de 2 µg/ml d'albumine bovine; c) moins de 1 mg/ml d'un réactif de récolte enzymatiquement actif; et d) la composition est sensiblement exempte de contamination par des mycoplasmes, des endotoxines et des microbes.

Designated States

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.African Regional Intellectual Property Org. (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)Eurasian Patent Organization (EAPO) (AM, AZ, BY, KG, KZ, RU, TJ, TM)European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)African Intellectual Property Organization (OAPI) (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Publication Language

English (EN)

Filing Language

English (EN)